toxicity due to adding an experimental therapy or regimen. However, it has been reported that only 38% of recently published phase III randomized clinical trials in cancer achieved results with statistical significance. 3 In this study, therefore, we examined the ability of positive phase II studies in glioblastoma to predict positive phase III studies. Our goal was to identify trial factors and/ or possible biases that led to the movement of phase II trials into subsequent phase III trials that ultimately failed, in order to help develop strategies for overcoming those factors or biases in future trials.
Methods

Search Strategy
A PubMed electronic database search was performed by one of our authors (J.J.M. on March 16, 2016 ) to identify publications of phase III clinical trials in glioblastoma patients by limiting the search to clinical trials and using the search terms "glioblastoma AND phase III. " The title and abstract of each reference identified in the search (n = 166) were inspected for potential relevance, which led to the identification of 35 phase III trials (Supplementary Figure S1) . We limited our analysis to phase III trials conducted in the past 25 years; therefore, trials with enrollment occurring prior to 1991 (n = 6) were excluded. We also excluded phase III trials not examining an investigational chemotherapy agent (n = 4) and phase III trials stopped early owing to toxicity (n = 1).
Next we reviewed the remaining 24 phase III study manuscripts to identify which prior phase II studies the authors cited as the justification for proceeding with the phase III study. Then we reviewed the primary endpoints of these phase II studies. Each phase II study was considered positive or negative depending on whether it achieved its stated primary endpoint. We excluded phase III studies for which no prior phase II studies were performed (Supplementary  Table S1 ) and for which a prior phase II study was negative (Supplementary Table S2 ). For trials of malignant glioma, if a subset analysis was done in glioblastoma patients alone, then the results for the subset were used in determining whether the trial was positive. These exclusion criteria were applied to be able to accurately evaluate whether positive phase II clinical trials using investigational therapeutic agents or regimens could predict subsequent positive phase III clinical trials in glioblastoma. Any trial deemed relevant was fully reviewed by all authors before full appraisal and analysis.
Data Collection
Data collected on all selected trials included stage of disease at the time of the study (newly diagnosed or recurrent), study enrollment dates, phase of study, number of trial sites, primary endpoints, radiographic response criteria used (if any), total number of patients on the trial, percentage of glioblastoma patients on the trial, number of trial regimen arms, and number of patients on each arm. For each study arm, we further collected data regarding performance status, extent of resection (gross total, subtotal, or biopsy), age, best imaging response (complete, partial, or stable disease), median progression-free survival (PFS) time, percentage of patients progression free at 6 months, median overall survival time, and promoter methylation status of O 6 -DNA methylguanine-methyltransferase (MGMT), if available. Furthermore, we examined each study's definition of statistical success, whether the study reached its initial statistical definition of success, whether a historical or contemporary control group was used for comparisons, and, if applicable, which historical control group was utilized.
Results
We identified 7 phase III clinical trials in newly diagnosed glioblastoma and 4 phase III clinical trials in recurrent glioblastoma that met the inclusion criteria (Table 1) . Of these 11 phase III clinical trials in glioblastoma that were preceded by positive phase II studies, only 1 (9%) phase III study was subsequently positive.
All phase III studies in newly diagnosed glioblastoma were done as multicenter studies, with 86% (6/7) done in the international cooperative group setting. [4] [5] [6] [7] [8] [9] The only non-cooperative group phase III study was the Gliadel Wafer (carmustine) study, which was performed in a total of 38 centers in 14 countries. 10 Phase II Trials Cited in Reports of Phase III Trials for Newly Diagnosed Glioblastoma
The 7 phase III clinical trials in newly diagnosed glioblastoma cited 12 prior positive phase II clinical studies as justification for the trials (Table 1) .
Importance of the study
Glioblastoma is the most common malignant primary brain tumor in adults. However, resources are limited in this relatively rare disease. Little progress has been made in improving overall survival for glioblastoma patients, with minimal success noted in recent phase III clinical trials. With the increasing costs and high failure rate of phase III trials, there is an urgent need to increase the reliability of phase II trials of treatments for glioblastoma. This study identifies trial factors and/ or possible biases (such as lack of comparable control group, use of changing imaging criteria, and low threshold for definition of success) that lead to the movement of phase II trials into subsequent phase III trials that ultimately fail, in order to help develop methods for overcoming those factors or biases in future trials. 
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Study size and design
Of the 12 phase II studies, 9 (75%) were multicenter conducted at a mean of 12 sites. Three (25%) of the phase II studies were international cooperative group trials, 11-13 2 (17%) were multinational studies conducted at more than 15 sites, 14,15 1 (8%) was a multinational study of carmustine wafers conducted at 4 sites, 16 2 (17%) were conducted at multiple sites in one country, 17,18 1 (8%) was done at 2 academic centers, 19 and the remaining 3 (25%) were performed at single academic centers. [20] [21] [22] These phase II studies enrolled patients during the time frame of 1988-2011. Half (6/12) of the phase II studies cited were done in the setting of recurrent glioblastoma.
A median of 58 (range 32-225) patients were enrolled on the 12 phase II trials. Four studies (33%) had 2 treatment arms, whereas the rest (66%) were single-arm studies. Of the studies with 2 arms, 2 used placebo wafers in one arm, 11, 16 while the other 2 compared 2 arms that both used experimental treatments. 15, 18 Primary endpoints Table 1 shows that the most common primary endpoints were PFS at 6 months (6 studies, 50%), followed by safety/ toxicity (4 studies, 33%), overall survival (3 studies, 25%), and imaging response rate (2 studies, 17%).
Radiographic response criteria
Sixty-seven percent (8/12) of the phase II studies reported that an imaging criterion was used for response assessment. The response assessment criteria used included the Macdonald (most common), Levin, and modified World Health Organization (WHO) criteria. The intervals between MRI scans to assess for response to treatment varied between the studies.
Study treatments
Chemotherapeutic and targeted agents examined in the 12 phase II studies were temozolomide, dose-dense temozolomide, temozolomide and cilengitide, bevacizumab, bevacizumab and irinotecan, carmustine wafers, and carmustine and cisplatin. Four (33%) of the phase II studies included targeted therapies (bevacizumab and cilengitide). Both targeted agents were determined to be unsafe for examination of target engagement using posttreatment tissue evaluation.
Control groups
Historical control groups were used for comparison in 75% (9/12) of the phase II studies. Historical data were extracted from reports of the European Organisation for Research and Treatment of Cancer (EORTC) trial 22981, a retrospective study of outcomes and prognostic factors in recurrent glioma patients enrolled on phase II clinical trials, recursive partitioning analysis of prognostic factors in 3 Radiation Therapy Oncology Group malignant glioma trials, multiple studies for determining 6-month PFS with salvage therapy or single-agent irinotecan, a phase II study of temozolomide versus procarbazine in patients with glioblastoma at first relapse, and an early trial using neoadjuvant teniposide and lomustine. Twenty-five percent (3/12) of the phase II studies included a control arm. Control treatments included placebo wafers (2/3 of the studies) and procarbazine (at relapse).
Prognostic biomarkers
MGMT was assessed in 42% (5/12) of the phase II studies. 13, 14, 17, 19, 22 All of the trials were single-arm studies, and MGMT was therefore not used for stratification. Two of the studies did not find any correlation between MGMT promoter methylation status of the tumors and PFS. 17, 22 Isocitrate dehydrogenase 1 (IDH1) mutation status was not examined in any of the studies.
Phase II Trials Cited in Reports of Phase III Recurrent Glioblastoma Trials
In our review of the 4 phase III clinical trials involving recurrent glioblastoma, we identified 7 prior positive phase II clinical studies (Table 1) . Three of the phase III studies were done as multicenter international studies, while the fourth study was done at 36 sites in the UK. 23 
Study size and design
Of the 7 phase II studies, 4 (57%) were multicenter international conducted at a mean of 19.7 sites. The phase II studies enrolled patients during the time frame of 1989-2008. All 7 of the phase II studies cited were done in the setting of recurrent glioblastoma.
A median of 79.7 (range, 30-225) patients were enrolled on the 7 phase II trials. Two studies had 2 treatment arms, whereas the rest (71%) were single-arm studies. Of the studies with 2 treatment arms, 1 used procarbazine for comparison, 15 and the other used placebo wafers. 11 
Primary endpoints
The most common primary endpoints were the rates of PFS at 6 months (4 studies, 57%), overall survival (2 studies, 29%), and imaging response (1 study, 14%).
Radiographic response criteria
Eighty-five percent (6/7) of the phase II studies reported that an imaging criterion was used for response assessment. The response assessment criteria used included the Macdonald (most common), Levin, and SWOG criteria and a 5-point grading system. The intervals between MRI scans to assess for response to treatment varied between the studies.
Study treatments
Chemotherapeutic and targeted agents examined in the phase II studies were cediranib, temozolomide, cintredekin besudotox, enzastaurin, imatinib plus hydroxyurea, and carmustine wafers. One (13%) of the phase II studies included a targeted therapy (cediranib), which included a circulating biomarker analysis.
Control group
Historical control groups were used in 71% (5/7) of the phase II studies. Historical studies used as controls included data from a phase II study of temozolomide versus procarbazine in patients with glioblastoma at first relapse, databases of patients treated with investigative regimens at the University of California-San Francisco, the outcomes and prognostic factors in recurrent glioma patients enrolled on phase II clinical trials, and a placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The other 29% (2/7) of the phase II studies included a control group arm. Control treatments included placebo wafers for the carmustine wafer study and procarbazine in the study comparing it with temozolomide.
Prognostic biomarkers
MGMT promoter methylation and IDH mutation status were not examined in any of the studies.
Discussion
Our study found that over the past 25 years, prior positive phase II clinical trials using investigational therapeutic agents or regimens were very poor predictors of a subsequent positive phase III clinical trial in glioblastoma patients. Even when limiting our examination to phase III trials with prior positive phase II studies, we found that 10 of 11 (91%) phase III trials did not achieve statistically significant results. Improving trial design practices in order to reduce phase III clinical trial failure in glioblastoma may enable the field of neuro-oncology to focus attention and resources on therapies with the highest likelihood of being successful.
Glioblastoma is well known to be extremely difficult to treat, with a poor prognosis despite multimodality treatment. 9 Several possible reasons have been proposed for why these tumors are so resistant to therapy, including tumoral heterogeneity, overlapping/redundant signaling pathways, and poor drug delivery to the brain, and these issues likely contribute to the failures of phase III trials. However, while glioblastoma is a relatively rare tumor type, with an age-adjusted annual incidence rate of 3.20 per 100 000 in adults in the United States, its human and economic cost is overwhelming. 24 Furthermore, the cost of clinical research continues to rise exponentially, as it is very expensive to move findings from bench to bedside and to perform all the regulatory studies (including phase I, II, and III clinical trials) to gain approval. 2 Increasingly onerous clinical trial bureaucracy and expanding regulatory requirements of uncertain benefit are often cited as justification for the high cost of new therapies. 2 With these increasing expenses for drug development approval and the limited resources available, it is imperative to examine potential ways to improve our ability to find beneficial treatments for glioblastoma patients such as stronger rationales for phase III trials. 2 Surprisingly, in our examination of phase III glioblastoma trials conducted over the past 25 years with an investigational chemotherapy or device, we found that more than half (12/23) of the phase III trials proceeded without a prior phase II study being performed or with a negative phase II study. Regarding the phase III studies without a prior phase II study: 2 had only prior phase I studies, 25,26 2 were using nimustine based on prior studies using carmustine, 27,28 and 1 had a prior negative phase III study in recurrence. 29 While promising phase I efficacy results are exciting, these small studies are designed to evaluate safety and tolerability and should not be used to assess efficacy (unless overwhelming success is observed in, for example, >80% of patents). These trends continue today, as several immunotherapy checkpoint inhibitor-based phase III studies (and randomized phase II registration studies) for glioblastoma are now under way because of promising results in other cancer types that remain to be validated in phase II trials of glioblastoma. Prior to performing a costly phase III study, a phase II trial to confirm efficacy is warranted. Pharmaceutical companies may find it more cost-effective to do an upfront randomized phase III trial than to carefully conduct phase II trials in recurrent glioblastoma patients; however, this approach may not be what is most beneficial for the patients, as it may expose additional patients to toxicity from an ineffective treatment and ultimately result in more failed phase III trials.
Regarding the phase III studies with a prior negative phase II clinical trial, one study was done on the basis of a phase II trial that switched the primary endpoint from 6-month PFS to imaging response rate in the middle of the trial. 30 Additionally, several of the phase III studies with a prior negative phase II study initially had the phase II study done in malignant gliomas that included lower-grade tumors such as anaplastic astrocytoma and thus may have included patients whose tumors were IDH1 mutated. If the experimental group in these phase II studies had a disproportionate number of IDH1 mutated tumors with a better prognosis irregardless of treatment, this may have led to the trial therapeutic falsely appearing beneficial. Also, in several malignant glioma studies, there did not appear to be any treatment benefit in the subset of glioblastoma patients, and yet a phase III study was conducted in glioblastoma patients using these treatments. 20, [30] [31] [32] [33] [34] Furthermore, 3 phase III studies were performed in newly diagnosed disease after phase II studies in recurrent disease were negative. 31, 32, 35 Using chemotherapy or novel agents in newly diagnosed glioblastoma that have previously failed to improve survival in patients with recurrent disease remains a practice of unclear utility and benefit.
One way to enhance phase II studies may be to include an active (contemporary) control group. Our study found that of the 20 phase II studies performed, only 5 (25%) had a control arm. Lately, the National Cancer Institute has strongly urged the conduct of randomized phase II trials in an attempt to reduce false-positive results. 36 However, others have postulated that the addition of an internal control arm to phase II trials is unattractive to patients and investigators. Clinical trial patients often desire to be on more aggressive treatment than the standard of care, and for the investigators, a control arm boosts the size of trials but
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diminishes the number of novel therapies being offered to patients.
Owing to the low rate of therapeutic success, the availability of historical controls, and the low rate of glioblastoma patients participating in clinical trials (<5%), it has been proposed that single-arm phase II studies take the best advantage of the limited number of patients accrued to be the most efficient way to screen novel agents/ approaches to discover potentially active therapies. 37 However, the incorporation of molecular markers into the new 2016 WHO diagnostic criteria will likely confound our ability to use historical controls who did not undergo molecular testing. 38 Despite attempts to develop new historical controls based on the incorporation of molecular data with other previously known prognostic factors such as age, Karnofsky performance status, and extent of resection, an active blinded placebo control group remains the gold standard to assess the efficacy of a new therapy. Additionally, small phase II studies have shown varying degrees of success in determining the importance of the biomarker MGMT. 17, 22, 39 Therefore, phase II trials containing a control arm (or at least a prospective stratification of molecular markers) may be necessary to determine the true efficacy of an investigational treatment. 40 Our study found that the use of prognostic biomarkers was limited, which is not surprising, as these markers were not identified until several studies were already completed. However, the stratification of patients with newly diagnosed glioblastoma in future trials based on MGMT promoter methylation and IDH1 mutation will be necessary going forward; however, the impact of these molecular markers at recurrence is unclear. 17, 22, 39, 41 Another idea to potentially increase the predictive ability of phase II studies is to require a higher threshold of success to move a trial forward, such as raising the 6-month PFS threshold to 60% in recurrent glioblastoma or even mandating an improvement in overall survival. A recent study found that post-market approval clinical trials did not indicate any overall survival benefit for 18 of the 36 cancer drugs approved by the FDA from 2008 to 2012 on the foundation of a surrogate endpoint (tumor shrinkage or PFS). 42 A follow-up study revealed that the estimated annual costs of 72% (13/18) of these drugs exceeded $100 000, including bevacizumab ($134 125) in glioblastoma. 43 With the recent focus on the value of cancer treatments by the American Society of Clinical Oncology and the European Society of Medical Oncology, raising the bar for the definition of outcome improvement in glioblastoma is warranted, as the 2 most recently FDA-approved treatment options, bevacizumab 44 and tumor-treating fields, 45 have both subsequently failed to demonstrate cost-effectiveness in newly diagnosed glioblastoma.
An additional issue worth addressing is that the present incentive arrangements in academics encourage small, innovative studies with low statistical power, often performed at only one or a few institutions. It is possible that half of these studies will arrive at invalid conclusions. 46 Moreover, with evolving knowledge of the heterogeneous genomic makeup of glioblastoma, there are increasing efforts to examine agents in small subgroups of patients; for example, our review included the CENTRIC EORTC 26071-22072 study, a phase III trial done in the subgroup of patients with methylated MGMT promoter based on prior phase II results. 8 The ICT-107 phase III trial currently under way in human leukocyte antigen A2-positive subjects is also based on a retrospective subgroup analysis from a prior phase II study. A recent study of phase III randomized controlled trials in gastrointestinal oncology found that industry-sponsored trials were more likely to report subgroup analyses. However, these subgroup results were frequently not supplemented by a significant interaction test. 47 Another study examining the statistical level of evidence of a single prespecified subgroup result in an overall statistically nonsignificant study found that in the case of a single trial, the inflation of the overall type I error is substantial and can be up to twice as large as the prespecified value, especially in relatively small subgroups. 48 Therefore, replication of encouraging subgroup results should be the standard methodology if a trial is nonsignificant overall. 49 Our study also showed the evolution of imaging criteria as a surrogate endpoint, with various phase II studies using different criteria. Notably, the criteria for response in imaging data are changing yet again with the use of immunotherapy, spurring the creation of new, specialized imaging response criteria for brain tumors. 50 The impact of the new imaging criteria remains speculative, as one theory for why such a large proportion of phase III solid tumor trials in cancer fail is that imaging endpoints/criteria are an inadequate surrogate for overall survival. It has been shown that a greater magnitude of response is associated with a better prognosis, but current trial endpoints do not measure quantitative improvements in response magnitude. 51 Therefore, the Biomarkers Consortium of the Foundation for the National Institutes of Health created the Volumetric CT for Precision Analysis of Clinical Trial Results project to collect imaging data from large phase III trials in non-small cell lung, renal cell, and colorectal carcinomas to develop and assess whatever quantitative imaging metrics most reliably predict trial results. Volumetric imaging might improve the reliability of using imaging data as an endpoint for response to therapy in glioblastoma trials, although a recent study found that in the BELOB trial, volumetric methods were not superior to 2-dimensional Response Assessment in Neuro-Oncology criteria for response evaluation. Alternatively, it has been proposed that examining the growth rate of a tumor after treatment may be the optimal way to evaluate the treatment's value. 52 Another potential improvement entails changing prior thinking about clinical trial designs in neuro-oncology. Investigators working on other cancer types have started to explore adaptive trial designs, Bayesian statistics, and biomarkers, which may be a faster and more efficient way to look for signs of efficacy. 53 Biomarker group/treatment effect hypotheses are "advanced" from such trials for additional concentrated phase III testing when the predicted probability of success is high. These trials have spurred the development of similar trials in glioblastoma, with enrollment in the Individualized Screening Trial of Innovative Glioblastoma Therapies (INSIGHT) and Adaptive Global Innovative Learning Environment (AGILE) trials (both of which are adaptive clinical trials using Bayesian statistics) set to begin in 2017. Other, umbrella protocols have been developed to attract more personalized treatments, such as the National Center for Tumor Diseases Neuro MASTER MATCH program, which uses obligatory genome-wide methylation analyses and a glioma gene panel to treat newly diagnosed glioma.
Over the past 25 years in patients with glioblastoma, positive phase II clinical trials of investigational therapeutic agents or regimens have been poor predictors of subsequent statistical significance in phase III clinical trials. Our findings do not support the past common practice of initiating phase III studies based on the results of single-arm phase II studies comparing outcomes to historical benchmarks. Phase III studies for newly diagnosed glioblastoma patients should also not be performed relying solely on outcomes obtained from phase II studies of recurrent glioblastoma patients. In conclusion, the greatest basis for a successful phase III trial is likely the incorporation of an active drug with effective CNS infiltration that attains a positive result in a randomized phase II trial in the same patient population assessed in the phase III study.
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